Healthcare Distribution Alliance – Patients Move Us.
Share Print


HDA Statement on Attorneys General Opioid Investigation

September 19, 2017

ARLINGTON, Va. — Following today‚Äôs announcement on investigations regarding the opioid epidemic, John M. Gray, President and CEO of the Healthcare Distribution Alliance (HDA), released the following statement.

“Pharmaceutical distributors welcome the opportunity to have a full discussion about how, and why, opioids have been overprescribed and how our industry can be positive contributors to addressing this public health crisis and its root causes.”

“While distributors play a vital role as logistics companies, to suggest that they are responsible for the volume of opioids prescribed lacks a fundamental understanding of how the supply chain works and is regulated. Distributors have no ability to influence what prescriptions are written. The fact is that distributors don’t make medicines, market medicines, prescribe medicines or dispense them to consumers. Our role is to deliver medicines safely, securely and efficiently from manufacturers to pharmacies, hospitals and other healthcare institutions based on prescriptions written by licensed prescribers.”



The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s nonprofit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.


© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365